Cytidine-5′-diphosphocholine (Citicoline): A pilot study in patients with non-arteritic ischaemic optic neuropathy

European Journal of Neurology

Volumn 15, Issue 5, 2008, Pages 465-474

  Parisi, V ^a   Coppola, G ^a   Ziccardi, L ^a   Gallinaro, G ^a   Falsini, B ^b  

^a IRCCS FONDAZIONE BIETTI   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Cytidine 5 diphosphocholine; Non arteritic ischaemic optic neuropathy; Pattern electroretinogram; Visual evoked potential

Indexed keywords

CEBROLUX; CITICOLINE; UNCLASSIFIED DRUG; NOOTROPIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ELECTRORETINOGRAM; EVOKED VISUAL RESPONSE; HUMAN; ISCHEMIC OPTIC NEUROPATHY; PRIORITY JOURNAL; VISION; VISUAL ACUITY; VISUAL FIELD; CASE CONTROL STUDY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; ELECTRORETINOGRAPHY; FEMALE; MALE; METHODOLOGY; MIDDLE AGED; PHOTOSTIMULATION; PHYSIOLOGY; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; TIME;

AGED; CASE-CONTROL STUDIES; CYTIDINE DIPHOSPHATE CHOLINE; ELECTRORETINOGRAPHY; EVOKED POTENTIALS, VISUAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NOOTROPIC AGENTS; OPTIC NEUROPATHY, ISCHEMIC; PHOTIC STIMULATION; PILOT PROJECTS; TIME FACTORS; VISUAL ACUITY;

EID: 41849131801     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2008.02099.x     Document Type: Article

References (53)

1. Hayreh SS, Zimmerman B. Visual field abnormalities in non-arteritic anterior ischemic optic neuropathy: their pattern and prevalence at initial examination. Archives of ophthalmology 2005 123 : 1554 1562.
2. Swartz NG, Beck RW, Savino PJ, et al. Pain in anterior ischemic optic neuropathy. Journal of Neurophthalmology 1995 15 : 9 10.
3. Repka MX, Savino PJ, Schatz NJ, Sergott RC. Clinical profile and long-term implications of anterior ischemic optic neuropathy. American Journal of Ophthalmology 1983 96 : 478 483.
4. Rucker JC, Biousse V, Newman NJ. Ischemic optic neuropathies. Current opinion in neurology 2004 17 : 27 35.
5. Chutorian AM, Winterkorn JM, Geffner M. Anterior ischemic optic neuropathy in children: case reports and review of the literature. Pediatric Neurology 2002 26 : 358 364.
6. Cheng MA, Sigurdson W, Tempelhoff R, Lauryssen C. Visual loss after spine surgery: a survey. Neurosurgery 2000 46 : 625 630.
7. Williams EL, Hart WM Jr., Tempelhoff R. Post-operative ischemic optic neuropathy. Anesthesia and analgesia 1995 80 : 1018 1029.
8. Mathews MK. Non-arteritic anterior ischemic optic neuropathy. Current opinion in ophthalmology 2005 16 : 341 345.
9. Johnson L, Gould T, Krobel G. Effect of levodopa and carbidopa on recovery of visual function in patients with non-arteritic anterior ischemic optic neuropathy of longer than six months duration. American Journal of Ophthalmology 1996 121 : 77 83.
10. Simsek T, Eryilmaz T, Acaroglu G. Efficacy of levodopa and carbidopa on visual function in patients with non-arteritic anterior ischaemic optic neuropathy. International journal of clinical practice 2005 59 : 287 290.
11. Ischemic Optic Neuropathy Decompression Trial Research Group. Optic nerve decompression surgery for non-ischemic optic neuropathy (NAION) is not effective and may be harmful. The Journal of the American Medical Association 1995 273 : 625 632.
12. Arnold A, Levin L. Treatment of ischemic optic neuropathy. Seminars in Ophthalmology 2002 17 : 39 46.
13. Wilhelm B, Ludtke H, Wilhelm H, Group TBs. Efficacy and tolerability of 0.2% brimonidine tartrate for the treatment of acute non-arteritic anterior ischemic optic neuropathy (NAION): a 3-month, double-masked, randomised, placebo-controlled trial. Graefe's Archive for Clinical and Experimental Ophthalmology 2005 8 : 1 8.
14. Secades JJ, Frontera G. CDP-choline: pharmacological and clinical review. Methods and Findings in Experimental and Clinical Pharmacology 1995 17 (Suppl. B 1 54.
15. Weiss GB. Metabolism and actions of CDP-choline as an endogenous compound and administered exogenously as citicoline. Life Science 1995 56 : 637 660.
16. Tazaki Y, Sakai F, Otomo E, et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke 1988 19 : 211 216.
17. Calatayud MV, Calatayud PJB, Aso EJ. Effects of CDP-choline on the recovery of patients with head injury. Journal of the Neurological Sciences 1991 103 (Suppl S15 S18.
18. Cubells JM, Hernando C. Clinical trial on the use of cytidine diphosphate choline in Parkinson's disease. Clinical therapeutics 1988 10 : 664 671.
19. Alvarez XA, Mouzo R, Pichel V, et al. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. Methods and Findings in Experimental and Clinical Pharmacology 1999 21 : 633 644.
20. Witkovsky P. Dopamine and retinal function. Documenta ophthalmologica 2004 108 : 17 40.
21. Pecori Giraldi J, Virno M, Covelli G, et al. Therapeutic value of citicoline in the treatment of glaucoma (computerized and automated perimetric investigation). International Ophthalmology 1989 13 : 109 112.
22. Virno M, Pecori-Giraldi J, Liguori A, De Gregorio F. The protective effect of citicoline on the progression of the perimetric defects in glaucomatous patients (perimetric study with a 10-year follow-up). Acta Ophthalmologica Scandinavica 2000 232 : 56 57.
23. Agnoli A, Fioravanti M, Lechner H Efficacy of CDP-choline in chronic cerebral vascular diseases (CCVD). In: Proceedings of the International Meeting, 1984: Sorrento, Italy. Novel Biochemical, Pharmacological and Clinical Aspects of Cytidine-diphosphocholine. New York : Elsevier, 1985 305 308.
24. Boismare F, Le Poncin M, Lefrancois J, Lecordier JC. Action of cytidine diphosphocholine on functional and hemodynamic effects of cerebral ischemia in cats. Pharmacology 1978 17 : 15 20.
25. Cacabelos R, Caamano J, Gomez MJ, et al. Therapeutic effects of CDP-choline in Alzheimer's disease. Cognition, brain mapping, cerebrovascular hemodynamics, and immune factors. Annals of the New York Academy of Sciences 1996 777 : 399 403.
26. Kakihana M, Fukuda N, Suno M, Nagaoka A. Effects of CDP-choline on neurologic deficits and cerebral glucose metabolism in a rat model of cerebral ischemia. Stroke 1988 19 : 217 222.
27. Serra I, Alberghina M, Viola M, et al. Effect of CDP-choline on the biosynthesis of nucleic acids and proteins in brain regions during hypoxia. Neurochemical Research 1981 6 : 607 618.
28. Maffei L, Fiorentini A. Electroretinographic responses to alternating gratings before and after section of the optic nerve. Science 1981 211 : 953 955.
29. Celesia GG, Kaufman D, Cone SB. Simultaneous recording of pattern electroretinography and visual evoked potentials in multiple sclerosis. A method to separate demyelination from axonal damage to the optic nerve. Archives of Neurology 1986 43 : 1247 1252.
30. Parisi V, Manni G, Colacino G, Bucci MG. Cytidine-5′- diphosphocholine (citicoline) improves retinal and cortical responses in patients with glaucoma. Ophthalmology 1999 106 : 1126 1134.
31. Parisi V. Electrophysiological assessment of glaucomatous visual dysfunction during treatment with cytidine-5′-diphosphocholine (citicoline): a study of 8 years of follow-up. Documenta ophthalmologica 2005 110 : 91 102.
32. Osborne NN, Wood JP, Chidlow G, et al. Ganglion cell death in glaucoma: what do we really know? British Journal of Ophthalmology 1999 83 : 980 986.
33. Knox DL, Kerrison JB, Green WR. Histopathologic studies of ischemic optic neuropathy. Transactions of the American Ophthalmological Society 2000 98 : 203 222.
34. Osborne NN, Ugarte M, Chao M, et al. Neuroprotection in relation to retinal ischemia and relevance to glaucoma. Survey of Ophthalmology 1999 43 (Suppl 1 S102 S128.
35. Hayreh SS, Jonas JB. Optic disc morphology after arteritic anterior ischemic optic neuropathy. Ophthalmology 2001 108 : 1586 1594.
36. Gonzalez-Gay MA, Garcia-Porrua C, Miranda-Filloy JA, Martin J. Giant cell arteritis and polymyalgia rheumatica: pathophysiology and management. Drugs and Aging 2006 23 : 627 649.
37. Celesia GG, Kaufman D. Pattern ERGs and visual evoked potentials in maculopathies and optic nerve diseases. Investigative Ophthalmology and Visual Science 1985 26 : 726 735.
38. Froehlich JE, Kaufman DI. Effect of decreased retinal illumination on simultaneously recorded pattern electroretinograms and visual evoked potentials. Investigative Ophthalmology and Visual Science 1991 32 : 310 318.
39. Parisi V, Manni G, Centofanti M, et al. Correlation between optical coherence tomography, pattern electroretinogram, and visual evoked potentials in open-angle glaucoma patients. Ophthalmology 2001 108 : 905 912.
40. Parisi V, Manni G, Spadaro M, et al. Correlation between morphological and functional retinal impairment in multiple sclerosis patients. Investigative Ophthalmology and Visual Science 1999 40 : 2520 2527.
41. Parisi V, Miglior S, Manni G, et al. Clinical ability of pattern electroretinograms and visual evoked potentials in detecting visual dysfunction in ocular hypertension and glaucoma. Ophthalmology 2006 113 : 216 228.
42. Porciatti V, Schiavi C, Benedetti P, et al. Cytidine-5′- diphosphocholine improves visual acuity, contrast sensitivity and visually-evoked potentials of amblyopic subjects. Current Eye Research 1998 17 : 141 148.
43. Goracci G, Francescangeli E, Mozzi R, et al. Regulation of phospholipid metabolism by nucleotides in brain and transport of CDP-choline into brain. In: Proceedings of the International Meeting, 1984: Sorrento, Italy. Novel Biochemical, Pharmacological and Clinical Aspects of Cytidinediphosphocholine. New York : Elsevier, 1985 : 105 109.
44. Kennedy EP, Weiss SB. The function of cytidine coenzymes in the biosynthesis of phospholipids. The Journal of Biological Chemistry 1956 222 : 193 214.
45. Rejdak R, Toczolowski J, Solski J, et al. Citicoline treatment increases retinal dopamine content in rabbits. Ophtalmic Research 2002 34 : 146 149.
46. Witkovsky P, Dearry A. Functional roles of dopamine in the vertebrate retina. Progress in Retinal Research 1991 11 : 247 292.
47. Simon A, Nguyen-Legros J. Are there dopaminergic ganglion cells in the mammalian retina? Neurochemistry International 1995 27 : 279 283.
48. Peppe A, Stanzione P, Pierelli F, et al. Visual alterations in de novo Parkinson's disease: pattern electroretinogram latencies are more delayed and more reversible by levodopa than are visual evoked potentials. Neurology 1995 45 : 1144 1148.
49. Masson G, Mestre D, Blin O. Dopaminergic modulation of visual sensitivity in man. Fundamentals of Clinical Pharmacology 1993 7 : 449 463.
50. Sakamoto K, Liu C, Kasamatsu M, et al. Dopamine regulates melanopsin mRNA expression in intrinsically photosensitive retinal ganglion cells. European Journal of Neuroscience 2005 22 : 3129 3136.
51. Jackson GR, Owsley C. Visual dysfunction, neurodegenerative diseases, and aging. Neurologic Clinics 2003 21 : 709 728.
52. Grieb P, Rejdak R. Pharmacodynamics of citicoline relevant to the treatment of glaucoma. Journal of Neuroscience Research 2002 67 : 143 148.
53. Phillipson OT, Kilpatrick IC, Jones MW. Dopaminergic innervation of the primary visual cortex in the rat, and some correlations with human cortex. Brain Research Bulletin 1987 18 : 621 633.